Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Pegbelfermin in Healthy Participants
NCT03445208Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH), Liver Fibrosis (LF), Liver cirrhosis (LC) and 1 more (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration at 29 days, Time of maximum observed serum concentration at 29 days and 2 more. Started Feb 2018; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)Liver cirrhosis (LC)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03445208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445208.